Updates to the NCCN guidelines recommend HEPZATO KIT for use in hepatic-dominant uveal melanoma as a Category 2A treatment option.
Health Professionals
Lifileucel Approval Paves the Way for Personalized Minimally-Invasive T-Cell Therapies
The FDA’s accelerated approval of lifileucel (Amtagvi; Iovance Biotherapeutics) marks a major milestone in immunotherapy for metastatic melanoma, building on decades of research in tumor-infiltrating lymphocyte therapy.
New cancer vaccine method boosts potency and scope
Vaccines to treat cancers have been around since 2010, the first being approved for prostate cancer, and another in 2015 for melanoma.
Eikon Adds Nearly $351M to Conquer Phase III Development in Melanoma
Eikon’s lead candidate, EIK1001, is being tested for advanced melanoma. The candidate is currently in late-stage development, which the biotech will fund using Wednesday’s series D raise.